A phase I study of APX001 (oral) for the treatment of candidiasis
Latest Information Update: 19 Sep 2016
At a glance
- Drugs Fosmanogepix (Primary)
- Indications Aspergillosis; Candidiasis; Mycoses
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2016 New trial record
- 12 Sep 2016 According to an Amplyx Pharmaceuticals media release, company plans to initiate this phase 1 study of oral APX001 in late 2016.